Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2008

01.03.2008

Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells

verfasst von: Francesco Bertolini

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Anti-angiogenic drugs, alone or in combination with chemotherapeutics, are increasingly used by medical oncologists. In many cases, however, their mechanism of action and the tailoring of optimal dosage/schedule are still elusive. Circulating endothelial cell (CEC) and progenitor (CEP) number and viability are modulated in a large series of diseases including cancer, and look promising as surrogate biomarkers for the definition of the optimal biological dose of anti-angiogenic drugs and for patients’ stratification. Along with CECs and CEPs, potential EC- and CEP-related surrogate molecular markers such as VE-Cadherin and CD133 are currently under preclinical and clinical investigation.
Literatur
1.
2.
Folkman, J. (2007). Angiogenesis: An organizing principle for drug discovery? Naturalist Review Drug Discovery, 6, 273–286.CrossRef
3.
Conway, E. M., Collen, D., & Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovascular Research, 49, 507–521.PubMedCrossRef
4.
Hladovec, J., & Rossamn, P. (1973). Circulating endothelial cells isolated together with platelets and the experimental modification of their counts in rats. Thrombosis Research, 3, 665–674.CrossRef
5.
Lin, Y., Weisdorf, D. J., Solovey, A., & Hebbel, R. P. (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 105, 71–77.PubMed
6.
Asahara, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, 964–967.PubMedCrossRef
7.
Shi, Q., et al. (1998). Evidence for circulating bone marrow-derived endothelial cells. Blood, 92, 362–367.PubMed
8.
Dignat-George, F., & Sampol, J. (2000). Circulating endothelial cells in vascular disorders: New insights into an old concept. European Journal of Haematology, 65, 215–220.PubMedCrossRef
9.
Bertolini, F., et al. (2006). The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nature Reviews Cancer, 6, 835–845.PubMedCrossRef
10.
Blann, A. D., et al. (2005). Circulating endothelial cells. Biomarker of vascular disease. Thrombosis and Haemostasis, 93, 228–235.PubMed
11.
Rafii, S., et al. (2002). Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nature Reviews Cancer, 2, 826–835.PubMedCrossRef
12.
Melero-Martin, J. M., et al. (2007). In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood, 109, 4761–4768.PubMedCrossRef
13.
Nagano, M., et al. (2007). Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using umbilical cord blood. Blood, 110, 151–160.PubMedCrossRef
14.
Yoder, M. C., et al. (2007). Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood, 109, 1801–1809.PubMedCrossRef
15.
Lyden, D., et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine, 7, 1194–1201.CrossRef
16.
De Palma, M., et al. (2003). Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Medicine, 9, 789–795.CrossRef
17.
Gothert, J. R., et al. (2004). Genetically tagging endothelial cells in vivo: Bone marrow-derived cells do not contribute to tumor endothelium. Blood, 104, 1769–1777.PubMedCrossRef
18.
Duda, D. G., et al. (2006). Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood, 107, 2774–2776.PubMedCrossRef
19.
Monsky, W. L., et al. (2002). Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: Mammary fat pad versus cranial tumors. Clinical Cancer Research, 8, 1008–1013.
20.
Peters, B. A., et al. (2005). Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nature Medicine, 11, 261–262.CrossRef
21.
Spring, H., et al. (2005). Chemokines direct endothelial progenitors into tumor neovessels. Proceedings of the National Academy of Sciences of the United States of America, 102, 18111–18116.PubMedCrossRef
22.
Ruzinova, M. B., et al. (2003). Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell, 4, 277–289.PubMedCrossRef
23.
Shaked, Y., et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science, 313, 1785–1787.PubMedCrossRef
24.
Bertolini, F., et al. (2003). Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research, 63, 4342–4346.PubMed
25.
Furstenberger, G., et al. (2006). Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. British Journal of Cancer, 94, 524–531.PubMedCrossRef
26.
Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312, 1171–1175.PubMedCrossRef
27.
Conejo-Garcia, J. R., et al. (2004). Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nature Medicine, 10, 950–958.CrossRef
28.
Grunewald, M., et al. (2006). VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cells, 124, 175–189.CrossRef
29.
De Palma, M., et al. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cells, 8, 211–226.CrossRef
30.
Udagawa, T., et al. (2006). Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: Contribution of local and bone marrow-derived host cells. FASEB Journal, 20, 95–102.PubMedCrossRef
31.
Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820–827.PubMedCrossRef
32.
Hlatky, L., et al. (2002). Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn’t tell us. Journal of the National Cancer Institute, 94, 883–893.PubMed
33.
Jain, R. K. (2002). Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Seminars in Oncology, 29(6 Suppl 16), 3–9.PubMed
34.
Motzer, R. J., et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24, 16–24.PubMedCrossRef
35.
Morgan, B., et al. (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. Journal of Clinical Oncology, 2, 3955–3964.CrossRef
36.
Shaked, Y., et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cells, 7, 101–111.
37.
Mancuso, P., et al. (2001). Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 97, 3658–3661.PubMedCrossRef
38.
Zhang, H., et al. (2005). Circulating endothelial progenitor cells in multiple myeloma: Implications and significance. Blood, 105, 3286–3294.PubMedCrossRef
39.
Mancuso, P., et al. (2006). Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 108, 452–459.PubMedCrossRef
40.
Norden-Zfoni, A., et al. (2007). Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clinical Cancer Research, 13, 2643–2650.PubMedCrossRef
41.
Monestiroli, S., et al. (2001). Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Research, 61, 4341–4344.PubMed
42.
Jain, R. K. (2003). Molecular regulation of vessel maturation. Natural Medicines, 9, 685–693.CrossRef
43.
Batchelor, T. T., et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cells, 11, 83–95.CrossRef
44.
Kerbel, R. S., & Kamen, B. A. (2004). The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer, 4, 423–436.PubMedCrossRef
45.
Seaman, S., et al. (2007). Genes that distinguish physiological and pathological angiogenesis. Cancer Cells, 11, 539–554.CrossRef
46.
Smirnov, D. A., et al. (2006). Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Research, 66, 2918–2922.PubMedCrossRef
47.
van Beijnum, J. R., et al. (2006). Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature. Blood, 108, 2339–2348.PubMedCrossRef
48.
Kim, I., et al. (2005). CD144 (VE-cadherin). is transiently expressed by fetal liver hematopoietic stem cells. Blood, 106, 903–905.PubMedCrossRef
49.
Wang, L., O’Leary, H., Fortney, J., & Gibson, L. F. (2007). Ph+/VE-cadherin+ identifies a stem-cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood, prepublished online 16 July 2007. DOI 10.​1182/​blood-2007-01-068122.
50.
Rabascio, C., et al. (2004). Assessing tumor angiogenesis: Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Research, 64, 4373–4377.PubMedCrossRef
51.
Lin, E. H., et al. (2007). Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer, (Epub ahead of print, Jun 26, 2007).
52.
Yu, D., et al. (2007). Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clinical Cancer Research, 13, 3814–3824.PubMedCrossRef
53.
Mehra, N., et al. (2006). Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clinical Cancer Research, 12, 4859–4866.PubMedCrossRef
54.
Ayers, M., Fargnoli, J., Lewin, A., Wu, Q., & Platero, J. S. (2007). Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Research, 67, 6899–6906.PubMedCrossRef
55.
Kerbel, R. S. (1991). Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13, 31–36.PubMedCrossRef
56.
Hida, K., et al. (2004). Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Research, 64, 8249–8255.PubMedCrossRef
57.
Streubel, B., et al. (2004). Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. New England Journal of Medicine, 351, 250–259.PubMedCrossRef
58.
Rigolin, G. M., et al. (2006). Neoplastic circulating endothelial cells in multiple myeloma with 13 q14 deletion. Blood, 107, 2531–2535.PubMedCrossRef
59.
Rigolin, G. M., et al. (2007). Neoplastic circulating endothelial-like cells in patients with acute myeloid leukaemia. European Journal of Haematology, 78, 365–373.PubMedCrossRef
60.
Bergsmedh, A., et al. (2001). Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proceedings of the National Academy of Sciences of the United States of America, 98, 6407–6411.PubMedCrossRef
61.
Mortensen, K., Lichtenberg, J., Thomsen, P. D., & Larsson, L. I. (2004). Spontaneous fusion between cancer cells and endothelial cells. Cellular and Molecular Life Sciences, 61, 2125–2131.PubMedCrossRef
62.
van Heeckeren, W. J., Ortiz, J., Cooney, M. M., & Remick, S. C. (2007). Hypertension, proteinuria, and antagonism of VEGF signalling: Clinical toxicity, therapeutic target, or novel biomarker? Journal of Clinical Oncology, 25, 2993–2995.PubMedCrossRef
Metadaten
Titel
Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells
verfasst von
Francesco Bertolini
Publikationsdatum
01.03.2008
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-007-9110-y

Weitere Artikel der Ausgabe 1/2008

Cancer and Metastasis Reviews 1/2008 Zur Ausgabe

NON-THEMATIC REVIEW

Osteopontin: regulation in tumor metastasis

OriginalPaper

Immune cells as mediators of solid tumor metastasis

OriginalPaper

Metastasis signatures: genes regulating tumor–microenvironment interactions predict metastatic behavior

OriginalPaper

Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment

OriginalPaper

The Met tyrosine kinase receptor in development and cancer

OriginalPaper

A “class action” against the microenvironment: do cancer cells cooperate in metastasis?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise